Tech Company Financing Transactions
Medherant Funding Round
Medherant closed a $3.7 million venture capital round on 4/4/2023. Investors included Mercia Fund Management.
Transaction Overview
Company Name
Announced On
4/4/2023
Transaction Type
Venture Equity
Amount
$3,743,205
Round
Undisclosed
Investors
Mercia Fund Management (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its growth and research efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Venture Centre University of Warwick Science Park Sir Wi
Coventry, CV4 7EZ
UK
Coventry, CV4 7EZ
UK
Phone
Website
Email Address
Overview
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch®. The company's lead project is a testosterone patch for women. There is considerable interest in the transdermal delivery of drugs to overcome some of the disadvantages of oral administration, such as spikes in drug levels that can lead to side effects, and poor compliance. Patches are also a more convenient way to deliver drugs through the skin than gels and creams and provide better dose control.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Burt
Chief Financial Officer
James Robson
Co-Founder
David Haddleton
Browse more venture capital transactions:
Prev: 4/4/2023: Franklin venture capital transaction
Next: 4/4/2023: ChopValue venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs